...
首页> 外文期刊>Thoracic cancer. >Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment
【24h】

Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment

机译:肺腺癌患者Keap1突变患有低免疫细胞浸润和免疫环境的低活性

获取原文

摘要

Background Kelch-like ECH-associated protein 1 (KEAP1) has been identified as a cancer driver gene in lung adenocarcinoma (LUAD), and increased evidence has given us clues about the association of KEAP1 mutation and immune characteristics. We assessed the association between KEAP1 mutation and tumor microenvironment in LUAD systematically. Methods With the data collected from The Cancer Genome Atlas (TCGA), we evaluated the association of KEAP1 mutation with tumor infiltrating leukocytes (TILs), including dendritic cell, CD8 T cell, CD4 T cell, neutrophil, B cells, and macrophage. Expression differences of the markers of those immune cells were also measured. We further compared the expression of antigen presentation genes and chemokines and the enrichment score of immune-related pathways. Results KEAP1 mutation had significant association with lower TILs and cytotoxic T lymphocyte. Strikingly, almost all of antigen presentation genes and chemokine showed lower expression in KEAP1-mutated tumors. Moreover, most of immune-related pathways were less active in KEAP1-mutated tumors. As expected, KEAP1-wild type LUADs favored better overall survival after immunotherapy. Finally, one patient harboring KEAP1 mutation along with a lack of immune cells infiltration in tumor microenvironment failed to respond to checkpoint inhibitor despite high tumor mutational burden (TMB). Conclusions KEAP1 mutation has a significant effect on the tumor immune milieu of LUAD and may play as a predictive biomarker of immunotherapy for LUAD patients.
机译:背景技术Kelch样Ech相关蛋白1(Keap1)已被鉴定为肺腺癌(Luad)的癌症驾驶基因,并且增加了对Keap1突变和免疫特征的关联的线索。我们系统地评估了keap1突变与肿瘤微环境之间的关联。方法具有从癌症基因组Atlas(TCGA)收集的数据,我们评估了Keap1突变与肿瘤渗透白细胞(TIL)的关联,包括树突细胞,CD8 T细胞,CD4 T细胞,中性粒细胞,B细胞和巨噬细胞。还测量了这些免疫细胞标记的表达差异。我们进一步比较了抗原呈递基因和趋化因子的表达以及免疫相关途径的富集评分。结果Keap1突变与较低的TIL和细胞毒性T淋巴细胞具有显着关系。尖锐的是,几乎所有抗原呈递基因和趋化因子都在Keap1突变的肿瘤中显示出较低的表达。此外,大多数免疫相关途径在Keap1突变的肿瘤中不太活跃。如预期的那样,Keap1-Wild Luads在免疫疗法后有利于更好的整体存活。最后,尽管高肿瘤突变负担(TMB),但患有Keap1突变的一名患者患有Keap1突变的患者患者缺乏免疫细胞浸润性未能响应检查点抑制剂。结论Keap1突变对拉德的肿瘤免疫环境有显着影响,并可作为管道患者的免疫疗法的预测生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号